Elanco Authorizes First-Ever $600 Million Share Repurchase Program
Elanco Animal Health Incorporated will buy back up to $600 million of common stock following a faster-than-expected reduction in its net leverage ratio.
Elanco Animal Health Incorporated authorized its first-ever share repurchase program, allowing for the buyback of up to $600 million of common stock. The board's decision follows the company's achievement of a net leverage ratio below 3.0 times faster than anticipated, including a reduction of approximately three-quarters of a turn in 2026 year-to-date.
Financial reports show the company generated $362 million in free cash flow by the end of the third quarter and is currently tracking ahead of its $1 billion cumulative free cash flow target for 2026 to 2028. Despite the buyback, the company intends to maintain a balanced capital allocation framework that prioritizes continued debt reduction and investment in its product development pipeline.
Elanco projects multi-year growth characterized by mid-single digit revenue increases, high single digit adjusted EBITDA growth, and low double digit adjusted EPS growth. The company noted that the actual timing and amount of the repurchases will depend on regulatory requirements, stock price, and market conditions.